BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 2004;72:114-22. [PMID: 14688088 DOI: 10.1128/IAI.72.1.114-122.2004] [Cited by in Crossref: 133] [Cited by in F6Publishing: 77] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 2008;15:499-505. [PMID: 18184825 DOI: 10.1128/CVI.00400-07] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
2 Gor DO, Ding X, Briles DE, Jacobs MR, Greenspan NS. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun 2005;73:1304-12. [PMID: 15731027 DOI: 10.1128/IAI.73.3.1304-1312.2005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
3 Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Yamamoto M, Akiyoshi K, Kiyono H. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013;81:1625-34. [PMID: 23460513 DOI: 10.1128/IAI.00240-13] [Cited by in Crossref: 97] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
4 Salcedo-Rivillas C, Debrie AS, Miyaji EN, Ferreira JM Jr, Raw I, Locht C, Ho PL, Mielcarek N, Oliveira ML. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. Clin Vaccine Immunol 2014;21:972-81. [PMID: 24807055 DOI: 10.1128/CVI.00134-14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Ricci S, Gerlini A, Pammolli A, Chiavolini D, Braione V, Tripodi SA, Colombari B, Blasi E, Oggioni MR, Peppoloni S, Pozzi G. Contribution of different pneumococcal virulence factors to experimental meningitis in mice. BMC Infect Dis 2013;13:444. [PMID: 24059458 DOI: 10.1186/1471-2334-13-444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
6 Otczyk DC, Cripps AW. Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines. Pneumonia (Nathan) 2013;2:2-15. [PMID: 31463182 DOI: 10.15172/pneu.2013.2/229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Genschmer KR, Accavitti-Loper MA, Briles DE. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine 2013;32:39-47. [PMID: 24211169 DOI: 10.1016/j.vaccine.2013.10.080] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
8 Visan L, Rouleau N, Proust E, Peyrot L, Donadieu A, Ochs M. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism. Hum Vaccin Immunother 2018;14:489-94. [PMID: 29135332 DOI: 10.1080/21645515.2017.1403698] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
9 Li J, Szalai AJ, Hollingshead SK, Nahm MH, Briles DE. Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect Immun 2009;77:464-71. [PMID: 19001076 DOI: 10.1128/IAI.00892-08] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
10 Propst-Graham KL, Preheim LC, Vander Top EA, Snitily MU, Gentry-Nielsen MJ. Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol. 2007;7:94. [PMID: 17956621 DOI: 10.1186/1471-2180-7-94] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
11 Huang J, Gingerich AD, Royer F, Paschall AV, Pena-Briseno A, Avci FY, Mousa JJ. Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection. Infect Immun 2021;89:e00747-20. [PMID: 33649050 DOI: 10.1128/IAI.00747-20] [Reference Citation Analysis]
12 Hiscox TJ, Chakravorty A, Choo JM, Ohtani K, Shimizu T, Cheung JK, Rood JI. Regulation of virulence by the RevR response regulator in Clostridium perfringens. Infect Immun 2011;79:2145-53. [PMID: 21402758 DOI: 10.1128/IAI.00060-11] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
13 Khan N, Qadri RA, Sehgal D. Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies. Clin Vaccine Immunol 2015;22:99-107. [PMID: 25410204 DOI: 10.1128/CVI.00001-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vadesilho CF, Ferreira DM, Gordon SB, Briles DE, Moreno AT, Oliveira ML, Ho PL, Miyaji EN. Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC. Clin Vaccine Immunol 2014;21:940-8. [PMID: 24807052 DOI: 10.1128/CVI.00239-14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
15 Lima FA, Ferreira DM, Moreno AT, Ferreira PC, Palma GM, Ferreira JM Jr, Raw I, Miyaji EN, Ho PL, Oliveira ML. Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice. Clin Vaccine Immunol 2012;19:1382-92. [PMID: 22761301 DOI: 10.1128/CVI.00171-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
16 Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JM Jr, Pimenta FC, Andrade AL, Miyaji EN. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010;17:439-46. [PMID: 20089795 DOI: 10.1128/CVI.00430-09] [Cited by in Crossref: 65] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
17 Moreno AT, Oliveira ML, Ho PL, Vadesilho CF, Palma GM, Ferreira JM Jr, Ferreira DM, Santos SR, Martinez MB, Miyaji EN. Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC. Clin Vaccine Immunol 2012;19:499-507. [PMID: 22336290 DOI: 10.1128/CVI.05706-11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
18 Khan N, Jan AT. Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol 2017;8:742. [PMID: 28512452 DOI: 10.3389/fmicb.2017.00742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
19 Briles DE, Novak L, Hotomi M, van Ginkel FW, King J. Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci. Infect Immun 2005;73:6945-51. [PMID: 16177374 DOI: 10.1128/IAI.73.10.6945-6951.2005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
20 Schachern PA, Tsuprun V, Cureoglu S, Ferrieri PA, Briles DE, Paparella MM, Juhn SK. Effect of apolactoferrin on experimental pneumococcal otitis media. Arch Otolaryngol Head Neck Surg 2010;136:1127-31. [PMID: 21079169 DOI: 10.1001/archoto.2010.192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
21 Akbari E, Negahdari B, Faraji F, Behdani M, Kazemi-Lomedasht F, Habibi-Anbouhi M. Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae. Biotechnol Rep (Amst) 2019;24:e00385. [PMID: 31763198 DOI: 10.1016/j.btre.2019.e00385] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Swiatlo E, King J, Nabors GS, Mathews B, Briles DE. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Infect Immun 2003;71:7149-53. [PMID: 14638806 DOI: 10.1128/IAI.71.12.7149-7153.2003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
23 Khan MN, Pichichero ME. The host immune dynamics of pneumococcal colonization: implications for novel vaccine development. Hum Vaccin Immunother 2014;10:3688-99. [PMID: 25668673 DOI: 10.4161/21645515.2014.979631] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
24 da Silva MA, Converso TR, Gonçalves VM, Leite LCC, Tanizaki MM, Barazzone GC. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. Clin Vaccine Immunol 2017;24:e00118-17. [PMID: 28637805 DOI: 10.1128/CVI.00118-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13:1004-9. [PMID: 16960111 DOI: 10.1128/CVI.00112-06] [Cited by in Crossref: 143] [Cited by in F6Publishing: 87] [Article Influence: 8.9] [Reference Citation Analysis]
26 Wiedinger K, Pinho D, Bitsaktsis C. Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice. Ther Adv Vaccines 2017;5:15-24. [PMID: 28344805 DOI: 10.1177/2051013617691041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
27 Tian H, Groner A, Boes M, Pirofski LA. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect Immun 2007;75:1643-50. [PMID: 17220309 DOI: 10.1128/IAI.01371-06] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
28 Melin MM, Hollingshead SK, Briles DE, Lahdenkari MI, Kilpi TM, Käyhty HM. Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae. Clin Vaccine Immunol 2008;15:1529-35. [PMID: 18753341 DOI: 10.1128/CVI.00181-08] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
29 Haleem KS, Ali YM, Yesilkaya H, Kohler T, Hammerschmidt S, Andrew PW, Schwaeble WJ, Lynch NJ. The Pneumococcal Surface Proteins PspA and PspC Sequester Host C4-Binding Protein To Inactivate Complement C4b on the Bacterial Surface. Infect Immun 2019;87:e00742-18. [PMID: 30323030 DOI: 10.1128/IAI.00742-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
30 Marshall H, José RJ, Kilian M, Petersen FC, Brown JS. Effects of Expression of Streptococcus pneumoniae PspC on the Ability of Streptococcus mitis to Evade Complement-Mediated Immunity. Front Microbiol 2021;12:773877. [PMID: 34880844 DOI: 10.3389/fmicb.2021.773877] [Reference Citation Analysis]
31 Acuna-Soto R, Viboud C, Chowell G. Influenza and pneumonia mortality in 66 large cities in the United States in years surrounding the 1918 pandemic. PLoS One 2011;6:e23467. [PMID: 21886792 DOI: 10.1371/journal.pone.0023467] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
32 Quin LR, Moore QC 3rd, McDaniel LS. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect Immun 2007;75:2067-70. [PMID: 17220305 DOI: 10.1128/IAI.01727-06] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
33 Wang D, Lu J, Yu J, Hou H, Leenhouts K, Van Roosmalen ML, Gu T, Jiang C, Kong W, Wu Y. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice. Immunol Invest 2018;47:403-15. [PMID: 29498560 DOI: 10.1080/08820139.2018.1439505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
34 Arêas AP, Oliveira ML, Miyaji EN, Leite LC, Ho PL. Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae. Infect Immun 2005;73:3810-3. [PMID: 15908419 DOI: 10.1128/IAI.73.6.3810-3813.2005] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
35 van den Broek B, van der Flier M, de Groot R, de Jonge MI, Langereis JD. Common Genetic Variants in the Complement System and their Potential Link with Disease Susceptibility and Outcome of Invasive Bacterial Infection. J Innate Immun 2020;12:131-41. [PMID: 31269507 DOI: 10.1159/000500545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Loughran AJ, Orihuela CJ, Tuomanen EI. Streptococcus pneumoniae: Invasion and Inflammation. Microbiol Spectr 2019;7. [PMID: 30873934 DOI: 10.1128/microbiolspec.GPP3-0004-2018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
37 Tostes RO, Rodrigues TC, da Silva JB, Schanoski AS, Oliveira ML, Miyaji EN. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae. PLoS One 2017;12:e0170157. [PMID: 28103277 DOI: 10.1371/journal.pone.0170157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Dalia AB, Standish AJ, Weiser JN. Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun 2010;78:2108-16. [PMID: 20160017 DOI: 10.1128/IAI.01125-09] [Cited by in Crossref: 87] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
39 Goulart C, da Silva TR, Rodriguez D, Politano WR, Leite LC, Darrieux M. Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One 2013;8:e59605. [PMID: 23533636 DOI: 10.1371/journal.pone.0059605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
40 Shaper M, Hollingshead SK, Benjamin WH Jr, Briles DE. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 2004;72:5031-40. [PMID: 15321996 DOI: 10.1128/IAI.72.9.5031-5040.2004] [Cited by in Crossref: 127] [Cited by in F6Publishing: 63] [Article Influence: 7.1] [Reference Citation Analysis]
41 Mukerji R, Mirza S, Roche AM, Widener RW, Croney CM, Rhee DK, Weiser JN, Szalai AJ, Briles DE. Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol 2012;189:5327-35. [PMID: 23105137 DOI: 10.4049/jimmunol.1201967] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
42 Li J, Wang JP, Ghiran I, Cerny A, Szalai AJ, Briles DE, Finberg RW. Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun 2010;78:3129-35. [PMID: 20439480 DOI: 10.1128/IAI.01263-09] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
43 Moschioni M, Pansegrau W, Barocchi MA. Adhesion determinants of the Streptococcus species. Microb Biotechnol 2010;3:370-88. [PMID: 21255337 DOI: 10.1111/j.1751-7915.2009.00138.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
44 Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PL. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 2010;5:e10863. [PMID: 20523738 DOI: 10.1371/journal.pone.0010863] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
45 Goulart C, Rodriguez D, Kanno AI, Silva JLSC, Leite LCC. Early pneumococcal clearance in mice induced by systemic immunization with recombinant BCG PspA-PdT prime and protein boost correlates with cellular and humoral immune response in bronchoalveolar fluids (BALF). Vaccine X 2020;4:100049. [PMID: 31891153 DOI: 10.1016/j.jvacx.2019.100049] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Li J, Glover DT, Szalai AJ, Hollingshead SK, Briles DE. PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun 2007;75:5877-85. [PMID: 17923519 DOI: 10.1128/IAI.00839-07] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
47 Kerr AR, Paterson GK, Riboldi-Tunnicliffe A, Mitchell TJ. Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3. Infect Immun 2005;73:4245-52. [PMID: 15972516 DOI: 10.1128/IAI.73.7.4245-4252.2005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
48 Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia. J Infect Dis 2015;212:1939-48. [PMID: 26123562 DOI: 10.1093/infdis/jiv341] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Goonetilleke UR, Ward SA, Gordon SB. Could proteomic research deliver the next generation of treatments for pneumococcal meningitis? Interdiscip Perspect Infect Dis 2009;2009:214216. [PMID: 19503804 DOI: 10.1155/2009/214216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Cron LE, Stol K, Burghout P, van Selm S, Simonetti ER, Bootsma HJ, Hermans PW. Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun 2011;79:3697-710. [PMID: 21768284 DOI: 10.1128/IAI.01383-10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
51 Cao J, Chen T, Gong Y, Ying B, Li D, Xu W, Zhang X, Wang L, Yin Y. Molecular mechanisms of the secretion of cytokines and chemokines from human monocytes activated by pneumococcal surface protein A (PspA): Roles of mitogen-activated protein kinases and NF-kappaB. Microb Pathog 2010;48:220-9. [PMID: 20227479 DOI: 10.1016/j.micpath.2010.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
52 Ochs MM, Bartlett W, Briles DE, Hicks B, Jurkuvenas A, Lau P, Ren B, Millar A. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog 2008;44:204-14. [PMID: 18006268 DOI: 10.1016/j.micpath.2007.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
53 Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 2009;77:4518-28. [PMID: 19687204 DOI: 10.1128/IAI.00486-09] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
54 Chen X, Li B, Yu J, Zhang Y, Mo Z, Gu T, Kong W, Zhang Y, Wu Y. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant. Med Microbiol Immunol 2019;208:215-26. [PMID: 30707297 DOI: 10.1007/s00430-019-00579-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
55 Goulart C, Rodriguez D, Kanno AI, Converso TR, Lu YJ, Malley R, Leite LCC. A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis. Clin Vaccine Immunol 2017;24:e00133-17. [PMID: 28768668 DOI: 10.1128/CVI.00133-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
56 Saumyaa, Pujanauski L, Colino J, Flora M, Torres RM, Tuomanen E, Snapper CM. Pneumococcal Surface Protein A Plays a Major Role in Streptococcus pneumoniae-Induced Immunosuppression. J Immunol 2016;196:3677-85. [PMID: 27029587 DOI: 10.4049/jimmunol.1502709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Ng WL, Tsui HC, Winkler ME. Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae. J Bacteriol 2005;187:7444-59. [PMID: 16237028 DOI: 10.1128/JB.187.21.7444-7459.2005] [Cited by in Crossref: 96] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
58 Zhang Y, Guo X, Guo M, Chen X, Li B, Yu J, Gu T, Kong W, Wu Y. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections. Immunol Res 2019;67:398-407. [PMID: 31773490 DOI: 10.1007/s12026-019-09107-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Katsura H, Piao Z, Iwatsuki-Horimoto K, Akeda Y, Watanabe S, Horimoto T, Oishi K, Kawaoka Y. A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection. J Virol 2014;88:13410-7. [PMID: 25210171 DOI: 10.1128/JVI.01205-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
60 Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun 2009;77:1502-13. [PMID: 19168739 DOI: 10.1128/IAI.01075-08] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
61 Moffitt K, Malley R. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother 2016;12:383-92. [PMID: 26535755 DOI: 10.1080/21645515.2015.1087625] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
62 Andre GO, Converso TR, Politano WR, Ferraz LF, Ribeiro ML, Leite LC, Darrieux M. Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol 2017;8:224. [PMID: 28265264 DOI: 10.3389/fmicb.2017.00224] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
63 Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun 2011;79:2819-28. [PMID: 21536790 DOI: 10.1128/IAI.01360-10] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
64 Hyams C, Trzcinski K, Camberlein E, Weinberger DM, Chimalapati S, Noursadeghi M, Lipsitch M, Brown JS. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun 2013;81:354-63. [PMID: 23147038 DOI: 10.1128/IAI.00862-12] [Cited by in Crossref: 59] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
65 German EL, Al-Hakim B, Mitsi E, Pennington SH, Gritzfeld JF, Hyder-Wright AD, Banyard A, Gordon SB, Collins AM, Ferreira DM. Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging. Pneumonia (Nathan) 2018;10:5. [PMID: 29992080 DOI: 10.1186/s41479-018-0048-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Colichio GB, Oliveira GS, Rodrigues TC, Oliveira MLS, Miyaji EN. Efficacy of a Protein Vaccine and a Conjugate Vaccine Against Co-colonization with Vaccine-type and Non-vaccine Type Pneumococci in Mice. Pathogens 2020;9:E278. [PMID: 32290340 DOI: 10.3390/pathogens9040278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Greene CJ, Marks LR, Hu JC, Reddinger R, Mandell L, Roche-Hakansson H, King-Lyons ND, Connell TD, Hakansson AP. Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization. Infect Immun 2016;84:1693-703. [PMID: 27001538 DOI: 10.1128/IAI.01478-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
68 Vashishta M, Khan N, Mehto S, Sehgal D, Natarajan K. Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner. PLoS One 2015;10:e0133601. [PMID: 26214513 DOI: 10.1371/journal.pone.0133601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
69 Sabharwal V, Ram S, Figueira M, Park IH, Pelton SI. Role of complement in host defense against pneumococcal otitis media. Infect Immun 2009;77:1121-7. [PMID: 19139190 DOI: 10.1128/IAI.01148-08] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
70 Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol 2012;19:1574-82. [PMID: 22855389 DOI: 10.1128/CVI.00393-12] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
71 Miyaji EN, Vadesilho CF, Oliveira ML, Zelanis A, Briles DE, Ho PL. Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins. Clin Vaccine Immunol 2015;22:213-20. [PMID: 25520146 DOI: 10.1128/CVI.00692-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
72 Haughney SL, Petersen LK, Schoofs AD, Ramer-Tait AE, King JD, Briles DE, Wannemuehler MJ, Narasimhan B. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomater 2013;9:8262-71. [PMID: 23774257 DOI: 10.1016/j.actbio.2013.06.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
73 Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, Briles DE, Hollingshead SK, Leite LC. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun 2007;75:5930-8. [PMID: 17923518 DOI: 10.1128/IAI.00940-07] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
74 Hotomi M, Yuasa J, Briles DE, Yamanaka N. Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization. Folia Microbiol (Praha) 2016;61:375-83. [PMID: 26803756 DOI: 10.1007/s12223-016-0445-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
75 Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infect Immun 2012;80:1166-80. [PMID: 22158740 DOI: 10.1128/IAI.05511-11] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
76 Sempere J, Llamosí M, Del Río Menéndez I, López Ruiz B, Domenech M, González-Camacho F. Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates. Vaccines (Basel) 2021;9:181. [PMID: 33672701 DOI: 10.3390/vaccines9020181] [Reference Citation Analysis]
77 Daniels CC, Kim KH, Burton RL, Mirza S, Walker M, King J, Hale Y, Coan P, Rhee DK, Nahm MH, Briles DE. Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A. Clin Vaccine Immunol 2013;20:1549-58. [PMID: 23925886 DOI: 10.1128/CVI.00371-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
78 Lu L, Ma Z, Jokiranta TS, Whitney AR, DeLeo FR, Zhang JR. Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol 2008;181:7138-46. [PMID: 18981135 DOI: 10.4049/jimmunol.181.10.7138] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
79 Mattos-Graner RO, Duncan MJ. Two-component signal transduction systems in oral bacteria. J Oral Microbiol 2017;9:1400858. [PMID: 29209465 DOI: 10.1080/20002297.2017.1400858] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]